Lv42
660 积分 2022-09-27 加入
Bevacizumab: in previously treated glioblastoma
10天前
已完结
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
10天前
已完结
KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRASG12D-mutant pancreatic cancer: a phase 1b/2 trial
1个月前
已完结
Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial
1个月前
已完结
Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations to assess therapeutic responses
1个月前
已完结
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer
1个月前
已完结
The impact of concomitant medications on treatment outcomes in patients with cancer receiving immune checkpoint inhibitors
1个月前
已完结
Report of two cases of pseudoprogression in patients with non–small cell lung cancer treated with nivolumab—including histological analysis of one case after tumor regression
2个月前
已完结
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
2个月前
已完结
Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4)
3个月前
已关闭
皖公网安备34019202002308
